Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
442.17
-1.08 (-0.24%)
At close: Sep 4, 2026
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.45B CHF in the half year ending June 30, 2026, with 2.26% growth. This brings the company's revenue in the last twelve months to 62.96B, down -0.83% year-over-year. In the year 2025, Roche Holding AG had annual revenue of 63.36B with 1.54% growth.
Revenue (ttm)
62.96B CHF
Revenue Growth
-0.83%
P/S Ratio
4.52
Revenue / Employee
609.78K CHF
Employees
103,249
Market Cap
352.29B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | 59.50B | 3.75B | 6.73% |
| Dec 31, 2017 | 55.75B | 3.11B | 5.91% |
| Dec 31, 2016 | 52.64B | 2.23B | 4.43% |
| Dec 31, 2015 | 50.40B | 537.00M | 1.08% |
| Dec 31, 2014 | 49.87B | 1.25B | 2.58% |
| Dec 31, 2013 | 48.61B | 1.17B | 2.46% |
| Dec 31, 2012 | 47.44B | 3.33B | 7.55% |
| Dec 31, 2011 | 44.11B | -5.05B | -10.28% |
| Dec 31, 2010 | 49.17B | -1.98B | -3.88% |
| Dec 31, 2009 | 51.15B | 3.25B | 6.78% |
| Dec 31, 2008 | 47.90B | -472.00M | -0.98% |
| Dec 31, 2007 | 48.38B | 4.94B | 11.38% |
| Dec 31, 2006 | 43.43B | 6.47B | 17.52% |
| Dec 31, 2005 | 36.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 594.41M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 141.01M |
| Northwest Biotherapeutics | 2.17M |
| Silence Therapeutics | 615.00K |
| Comjoyful International Company | 564.97K |
| Scientist Home Future Health | 400.74K |
Roche Holding AG News
- 4 days ago - Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies - Business Wire
- 4 days ago - Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion - GuruFocus
- 4 days ago - H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi - TheFly
- 4 days ago - Simcere Zaiming Enters Exclusive Global License Agreement With Roche For SIM0660 - Nasdaq
- 5 days ago - Roche signs global licensing pact for Simcere's experimental blood cancer drug - Reuters
- 7 days ago - Roche launches mangrove plantation drive along Nethravathi - The Times of India
- 8 days ago - Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says - Reuters
- 8 days ago - BioNTech Kills a Cancer Trial Roche Helped Build - GuruFocus